
AstraZeneca PLC
AZNHealthcare|Drug Manufacturers - General|GB
$186.43
-0.42 (-0.22%)
DCF Value
$500.17
Graham Number
$72.85
Cash / Share
$5.23
Financials
Financial Snapshot
Market Cap
$289.13B
Enterprise Value
$314.95B
Revenue (TTM)
$62.17B
Net Income (TTM)
$10.99B
Cash & Investments
$8.15B
Net Cash
-$25.98B
Free Cash Flow (TTM)
$9.32B
Operating CF (TTM)
$13.33B
Debt/Equity
0.66
Cash Runway & Burn Rate
Company is cash-flow positive.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $5.90B | $4.55B | $5.68B | $6.22B | $7.99B | $6.40B | $6.24B | $5.86B | $5.53B | $5.74B | $8.15B | |
| Operating Cash Flow | $4.14B | $3.58B | $2.62B | $2.97B | $4.80B | $5.96B | $9.81B | $10.35B | $11.86B | $14.57B | $13.33B | |
| Free Cash Flow | $1.83B | $1.96B | $1.25B | $509.0M | $2.19B | $3.76B | $7.24B | $6.57B | $7.28B | $8.67B | $9.32B | |
| Capital Expenditure | -$2.31B | -$1.62B | -$1.37B | -$2.46B | -$2.61B | -$2.20B | -$2.57B | -$3.78B | -$4.59B | -$5.91B | -$4.01B | |
| Financing Cash Flow | -$1.32B | -$2.94B | -$2.04B | -$1.76B | -$2.20B | $3.65B | -$6.82B | -$6.57B | -$4.00B | -$7.54B | -$5.39B |
R&D Spending
R&D (TTM)
$15.01B
R&D Intensity
24.1%
R&D Growth vs Prior
+5.4%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $23.00B | $22.46B | $22.09B | $24.38B | $26.62B | $37.42B | $44.35B | $45.81B | $54.07B | $58.74B | $62.17B | |
| R&D Expense | $5.89B | $5.76B | $5.93B | $6.06B | $5.99B | $9.74B | $9.76B | $10.94B | $13.58B | $14.23B | $15.01B | |
| R&D % of Revenue | 25.6% | 25.6% | 26.9% | 24.8% | 22.5% | 26.0% | 22.0% | 23.9% | 25.1% | 24.2% | 24.1% | |
| SG&A | $9.74B | $10.54B | $10.98B | $11.98B | $11.90B | $15.59B | $17.98B | $18.22B | $20.22B | $20.51B | $21.76B |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $23.00B | $22.46B | $22.09B | $24.38B | $26.62B | $37.42B | $44.35B | $45.81B | $54.07B | $58.74B | $62.17B | |
| Cost of Revenue | $4.13B | $4.32B | $4.94B | $4.92B | $5.30B | $12.44B | $12.39B | $8.27B | $10.21B | $10.63B | $12.38B | |
| Gross Profit | $18.88B | $18.15B | $17.15B | $19.46B | $21.32B | $24.98B | $31.96B | $37.54B | $43.87B | $48.11B | $49.79B | |
| R&D | $5.89B | $5.76B | $5.93B | $6.06B | $5.99B | $9.74B | $9.76B | $10.94B | $13.58B | $14.23B | $15.01B | |
| SG&A | $9.74B | $10.54B | $10.98B | $11.98B | $11.90B | $15.59B | $17.98B | $18.22B | $20.22B | $20.51B | $21.76B | |
| Operating Income | $4.90B | $3.68B | $3.39B | $2.92B | $5.16B | $1.06B | $3.76B | $8.19B | $10.00B | $13.74B | $14.71B | |
| Interest Expense | $1.37B | $1.36B | $1.37B | $1.40B | $1.27B | $1.28B | $1.33B | $1.59B | $1.68B | $1.69B | $1.77B | |
| Pretax Income | $3.55B | $2.23B | $1.99B | $1.55B | $3.92B | -$265.0M | $2.50B | $6.90B | $8.69B | $12.40B | $13.25B | |
| Net Income | $3.50B | $3.00B | $2.15B | $1.33B | $3.20B | $112.0M | $3.29B | $5.96B | $7.04B | $10.26B | $10.99B | |
| EPS (Diluted) | 2.76 | 2.37 | 1.70 | 1.03 | 2.44 | 0.08 | 2.11 | 3.81 | 4.50 | 6.54 | 7.01 | |
| EBITDA | $7.28B | $6.62B | $7.11B | $6.71B | $8.08B | $5.11B | $9.09B | $13.42B | $15.44B | $19.83B | $21.37B | |
| Shares Out. (M) | 1266.00 | 1267.00 | 1267.00 | 1301.00 | 1313.00 | 1427.00 | 1560.00 | 1562.00 | 1563.00 | 1562.00 | 1560.00 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.02B | $3.32B | $4.83B | $5.37B | $7.83B | $6.33B | $6.17B | $5.84B | $5.49B | $5.71B | $7.92B | |
| Short-Term Investments | $884.0M | $1.23B | $849.0M | $849.0M | $160.0M | $69.0M | $77.0M | $20.0M | $37.0M | $30.0M | $229.6M | |
| Total Current Assets | $13.26B | $13.15B | $15.59B | $15.56B | $19.54B | $26.24B | $22.59B | $25.05B | $25.83B | $28.72B | $31.39B | |
| Total Assets | $62.53B | $63.35B | $60.65B | $61.38B | $66.73B | $105.36B | $96.48B | $101.12B | $104.03B | $114.07B | $119.71B | |
| Total Current Liabilities | $15.26B | $16.38B | $16.29B | $18.12B | $20.31B | $22.59B | $26.29B | $30.54B | $27.87B | $30.62B | $31.21B | |
| Long-Term Debt | $16.51B | $17.39B | $19.20B | $15.73B | $17.50B | $28.13B | $22.96B | $22.36B | $26.51B | $24.71B | $26.42B | |
| Total Liabilities | $45.86B | $46.71B | $46.61B | $46.78B | $51.09B | $66.08B | $59.42B | $61.95B | $63.16B | $65.36B | $67.99B | |
| Stockholders' Equity | $14.85B | $14.96B | $12.47B | $13.13B | $15.62B | $39.27B | $37.04B | $39.14B | $40.79B | $48.67B | $51.64B | |
| Retained Earnings | $8.14B | $8.22B | $5.68B | $2.81B | $5.30B | $1.71B | -$574.0M | $4.52B | $3.16B | $10.97B | $14.04B |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $4.14B | $3.58B | $2.62B | $2.97B | $4.80B | $5.96B | $9.81B | $10.35B | $11.86B | $14.57B | $13.33B | |
| Capital Expenditure | -$2.31B | -$1.62B | -$1.37B | -$2.46B | -$2.61B | -$2.20B | -$2.57B | -$3.78B | -$4.59B | -$5.91B | -$4.01B | |
| Free Cash Flow | $1.83B | $1.96B | $1.25B | $509.0M | $2.19B | $3.76B | $7.24B | $6.57B | $7.28B | $8.67B | $9.32B | |
| Investing Cash Flow | -$3.97B | -$2.33B | $963.0M | -$657.0M | -$285.0M | -$11.06B | -$2.96B | -$4.06B | -$7.98B | -$6.81B | -$8.16B | |
| Financing Cash Flow | -$1.32B | -$2.94B | -$2.04B | -$1.76B | -$2.20B | $3.65B | -$6.82B | -$6.57B | -$4.00B | -$7.54B | -$5.39B | |
| Issuance of Stock | $47.0M | $43.0M | $34.0M | $3.52B | $30.0M | $29.0M | $29.0M | $33.0M | -$43.0M | -$481.0M | -$568.7M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$348.8M | |
| Net Debt Issuance | $2.48B | $224.0M | $1.47B | -$1.19B | $1.65B | $7.89B | -$1.20B | -$965.0M | $1.81B | -$1.65B | $793.3M | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $259.0M | $277.0M | $615.0M | $619.0M | $579.0M | $0.00 | $0.00 | $0.00 | |
| Net Change in Cash | -$1.13B | -$1.75B | $1.50B | $552.0M | $2.32B | -$1.51B | -$55.0M | -$346.0M | -$208.0M | $269.0M | -$251.4M |
Dilution Tracker
Shares Outstanding
1551M
5-Year Share Growth
+19.0%
Stock Issuance (TTM)
-$568.7M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 1266.00 | 1267.00 | 1267.00 | 1301.00 | 1313.00 | 1427.00 | 1560.00 | 1562.00 | 1563.00 | 1562.00 | 1560.00 | |
| Change vs Prior % | — | 0.1% | 0.0% | 2.7% | 0.9% | 8.7% | 9.3% | 0.1% | 0.1% | -0.1% | -0.1% | |
| Stock Issuance | $47.0M | $43.0M | $34.0M | $3.52B | $30.0M | $29.0M | $29.0M | $33.0M | -$43.0M | -$481.0M | -$568.7M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$348.8M | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $259.0M | $277.0M | $615.0M | $619.0M | $579.0M | $0.00 | $0.00 | $0.00 |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 82.1% | 80.8% | 77.7% | 79.8% | 80.1% | 66.8% | 72.1% | 82.0% | 81.1% | 81.9% | 80.1% | |
| Operating Margin % | 21.3% | 16.4% | 15.3% | 12.0% | 19.4% | 2.8% | 8.5% | 17.9% | 18.5% | 23.4% | 23.7% | |
| Net Margin % | 15.2% | 13.4% | 9.8% | 5.5% | 12.0% | 0.3% | 7.4% | 13.0% | 13.0% | 17.5% | 17.7% | |
| EBITDA Margin % | 31.6% | 29.5% | 32.2% | 27.5% | 30.4% | 13.7% | 20.5% | 29.3% | 28.6% | 33.8% | 34.4% | |
| FCF Margin % | 8.0% | 8.7% | 5.6% | 2.1% | 8.2% | 10.1% | 16.3% | 14.3% | 13.5% | 14.8% | 15.0% | |
| ROE % | 23.6% | 20.1% | 17.3% | 10.2% | 20.5% | 0.3% | 8.9% | 15.2% | 17.2% | 21.1% | 22.3% | |
| ROA % | 5.6% | 4.7% | 3.6% | 2.2% | 4.8% | 0.1% | 3.4% | 5.9% | 6.8% | 9.0% | 9.3% | |
| ROIC % | 9.5% | 7.5% | 7.3% | 5.1% | 8.5% | -0.5% | 5.0% | 9.3% | 10.3% | 13.0% | 13.1% | |
| R&D / Revenue % | 25.6% | 25.6% | 26.9% | 24.8% | 22.5% | 26.0% | 22.0% | 23.9% | 25.1% | 24.2% | 24.1% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -6.9% | -2.3% | -1.7% | 10.4% | 9.2% | 40.6% | 18.5% | 3.3% | 18.0% | 8.6% | |
| Gross Profit | -5.9% | -3.9% | -5.5% | 13.5% | 9.5% | 17.2% | 27.9% | 17.5% | 16.8% | 9.7% | |
| Operating Income | 19.2% | -25.0% | -7.9% | -13.7% | 76.5% | -79.5% | 255.8% | 118.1% | 22.1% | 37.4% | |
| Net Income | 23.9% | -14.2% | -28.2% | -38.1% | 139.4% | -96.5% | 2835.7% | 81.1% | 18.1% | 45.8% | |
| EPS (Diluted) | 23.8% | -14.1% | -28.3% | -39.4% | 136.9% | -96.7% | 2537.5% | 80.6% | 18.1% | 45.3% | |
| Operating Cash Flow | 24.7% | -13.7% | -26.8% | 13.4% | 61.6% | 24.3% | 64.5% | 5.5% | 14.7% | 22.9% | |
| Free Cash Flow | 241.6% | 6.9% | -36.3% | -59.2% | 330.8% | 71.6% | 92.3% | -9.3% | 10.8% | 19.2% | |
| R&D Expense | -1.8% | -2.3% | 3.0% | 2.1% | -1.1% | 62.5% | 0.3% | 12.0% | 24.2% | 4.8% | |
| SG&A Expense | -15.4% | 8.3% | 4.2% | 9.1% | -0.7% | 31.1% | 15.4% | 1.3% | 11.0% | 1.4% | |
| Total Assets | 4.0% | 1.3% | -4.3% | 1.2% | 8.7% | 57.9% | -8.4% | 4.8% | 2.9% | 9.6% | |
| Book Value / Share | -10.0% | -0.2% | -15.7% | 1.2% | 6.2% | 132.4% | -13.6% | 4.7% | 5.2% | 19.2% | |
| Debt | 11.7% | 5.9% | 7.3% | -4.6% | 11.8% | 50.6% | -5.0% | -1.8% | 5.2% | -1.4% | |
| Diluted Shares | 0.1% | 0.1% | 0.0% | 2.7% | 0.9% | 8.7% | 9.3% | 0.1% | 0.1% | -0.1% |
Valuation
P/E (TTM)26.16
10Y Low / Med / High19.45 / 41.39 / 1448.13
P/S4.63
10Y Low / Med / High2.96 / 4.58 / 5.39
P/B5.62
10Y Low / Med / High4.18 / 5.69 / 10.01
EV/EBITDA14.75
10Y Low / Med / High10.99 / 17.34 / 36.89
EV/Revenue5.05
10Y Low / Med / High3.48 / 5.04 / 5.92
P/FCF31.74
10Y Low / Med / High27.70 / 43.66 / 258.16
Intrinsic Value Models (per share)
DCF Value
$500.17
Graham Number
$72.85
Cash / Share
$5.23
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | 19.45 | 29.28 | 44.68 | 98.06 | 41.39 | 1448.13 | 64.25 | 35.29 | 28.63 | 26.59 | 26.16 | |
| P/S Ratio | 2.96 | 3.91 | 4.36 | 5.39 | 4.98 | 4.39 | 4.75 | 4.58 | 3.73 | 4.63 | 4.63 | |
| P/B Ratio | 4.59 | 5.87 | 7.72 | 10.01 | 8.48 | 4.18 | 5.69 | 5.37 | 4.94 | 5.59 | 5.62 | |
| EV/EBITDA | 10.99 | 15.45 | 15.54 | 21.49 | 17.94 | 36.89 | 25.74 | 17.34 | 14.65 | 14.93 | 14.75 | |
| EV/Revenue | 3.48 | 4.56 | 5.00 | 5.92 | 5.45 | 5.04 | 5.27 | 5.08 | 4.18 | 5.04 | 5.05 |
Analyst Estimates & Quality
Altman Z-Score
3.65
Safe
Piotroski F-Score
7
Strong
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $62.80B | $66.92B | $71.07B |
| Net Income | $15.85B | $17.66B | $19.65B |
| EPS | $10.26 | $11.34 | $12.61 |
| # Analysts (EPS) | 7 | 8 | 13 |
Dividends
Dividend/Share (TTM)
$3.20
Dividend Yield
1.72%
Frequency
Semi-Annual
Recent Payments
| Ex-Date | Pay Date | Amount | Frequency |
|---|---|---|---|
| Aug 7, 2026 | Sep 8, 2026 | $1.06 | Semi-Annual |
| Feb 20, 2026 | Mar 23, 2026 | $2.17 | Semi-Annual |
| Aug 8, 2025 | Sep 8, 2025 | $0.52 | Semi-Annual |
| Feb 21, 2025 | Mar 24, 2025 | $1.05 | Semi-Annual |
| Aug 9, 2024 | Sep 9, 2024 | $0.50 | Semi-Annual |
| Feb 22, 2024 | Mar 25, 2024 | $0.98 | Semi-Annual |
| Aug 10, 2023 | Sep 11, 2023 | $0.47 | Semi-Annual |
| Feb 23, 2023 | Mar 27, 2023 | $0.96 | Semi-Annual |
| Aug 11, 2022 | Sep 12, 2022 | $0.46 | Semi-Annual |
| Feb 24, 2022 | Mar 28, 2022 | $0.96 | Semi-Annual |
| Aug 12, 2021 | Sep 13, 2021 | $0.44 | Semi-Annual |
| Feb 25, 2021 | Mar 29, 2021 | $0.95 | Semi-Annual |
| Aug 13, 2020 | Sep 14, 2020 | $0.44 | Semi-Annual |
| Feb 27, 2020 | Mar 30, 2020 | $0.95 | Semi-Annual |
| Aug 8, 2019 | Sep 9, 2019 | $0.45 | Semi-Annual |
| Feb 28, 2019 | Mar 27, 2019 | $0.95 | Semi-Annual |
| Aug 9, 2018 | Sep 10, 2018 | $0.45 | Semi-Annual |
| Feb 15, 2018 | Mar 19, 2018 | $0.95 | Semi-Annual |
| Aug 9, 2017 | Sep 11, 2017 | $0.45 | Semi-Annual |
| Feb 15, 2017 | Mar 20, 2017 | $0.95 | Semi-Annual |
Revenue Segments
By Product
| Segment | 2019 | 2020 | 2021 | 2022 | 2023 | 2025 |
|---|---|---|---|---|---|---|
| Crestor | $1.28B | $1.18B | $1.10B | $1.05B | $1.11B | $1.22B |
| Arimidex | $225.0M | — | — | $99.0M | — | — |
| Atacand | $221.0M | — | — | — | — | — |
| Brilinta | $1.58B | — | — | $1.36B | $1.32B | $823.0M |
| Bydureon | $549.0M | — | — | $280.0M | $163.0M | — |
| Byetta | $110.0M | — | — | — | — | — |
| Calquence | $164.0M | — | — | $2.06B | $2.51B | $3.52B |
| Cardiovascular And Metabolic Diseases Products | $6.91B | — | — | — | — | — |
| Casodex | $200.0M | — | — | $78.0M | — | — |
| Daliresp Daxas | $215.0M | — | — | — | — | — |
| Duaklir | $77.0M | — | — | — | — | — |
| Farxiga | $1.54B | — | — | $4.38B | $5.96B | $8.40B |
| Fasenra | $704.0M | — | — | $1.40B | $1.55B | $1.98B |
| Faslodex | $892.0M | — | — | $334.0M | $297.0M | — |
| Imfinzi | $1.47B | — | — | $2.78B | $4.24B | $6.06B |
| Iressa | $423.0M | — | — | $114.0M | — | — |
| Losec Prilosec | $263.0M | — | — | — | — | — |
| Lynparza | $1.20B | — | — | $2.64B | $2.81B | $3.28B |
| Nexium | $1.48B | — | $1.33B | $1.28B | $945.0M | $816.0M |
| Oncology Products | $8.67B | — | — | — | — | — |
| Onglyza | $527.0M | — | — | $257.0M | $227.0M | — |
| Other Cardiovascular And Metabolic Diseases Products | $271.0M | — | — | — | — | — |
| Other Diabetes | $52.0M | — | — | — | — | — |
| Other Oncology Products | $94.0M | — | — | — | — | — |
| Other Products Others | $306.0M | — | — | — | — | — |
| Other Products | $2.60B | — | — | — | — | — |
| Other Respiratory Products | $390.0M | — | — | — | — | — |
| Pulmicort | $1.47B | — | — | $645.0M | $713.0M | $518.0M |
| Respiratory Products | $5.39B | — | — | — | — | — |
| Seloken Toprol Xl | $760.0M | — | — | — | — | — |
| Seroquel Xr Ir | $191.0M | — | — | — | — | — |
| Symbicort | $2.50B | — | — | $2.54B | $2.36B | $2.88B |
| Tagrisso | $3.19B | — | — | $5.44B | $5.80B | $7.25B |
| Zoladex | $813.0M | $888.0M | $948.0M | $927.0M | $952.0M | $1.11B |
| Bevespi | $42.0M | — | — | $58.0M | $58.0M | — |
| Lokelma | $14.0M | — | — | $289.0M | $412.0M | $698.0M |
| Synagis | $358.0M | — | — | $578.0M | $546.0M | $292.0M |
| Breztri | $2.0M | — | — | $398.0M | $677.0M | $1.20B |
| Lynparza And Koselugo | — | $460.0M | — | — | — | — |
| Other Collaboration Revenue | — | $46.0M | — | — | — | — |
| Royal Revenue | — | $62.0M | — | — | — | — |
| Lynparza/Koselugo | — | — | $400.0M | — | — | — |
| Other Ongoing Collaboration Revenue | — | — | $64.0M | — | — | — |
| Profit share revenue from product sales by collaboration partners | — | — | $200.0M | — | — | — |
| Royal income | — | — | $138.0M | — | — | — |
| Enhertu | — | — | $17.0M | $79.0M | $1.02B | $1.80B |
| Roxadustat | — | — | $174.0M | $197.0M | $271.0M | $274.0M |
| Collaboration Revenue | — | — | $12.0M | — | — | — |
| BioPharmaceuticals: total Respiratory & Immunology | — | — | — | $5.76B | — | — |
| CVRM | — | — | — | $9.19B | $10.59B | $12.76B |
| Daliresp/Daxas | — | — | — | $189.0M | $54.0M | — |
| FluMist | — | — | — | $175.0M | $216.0M | $272.0M |
| Kanuma | — | — | — | $160.0M | $171.0M | — |
| Koselugo | — | — | — | $208.0M | $331.0M | $662.0M |
| Oncology, Others | — | — | — | $44.0M | $224.0M | $425.0M |
| Ophatys | — | — | — | $33.0M | — | — |
| Other, Others | — | — | — | $340.0M | $231.0M | $156.0M |
| Rare Disease | — | — | — | $7.05B | $7.76B | $9.13B |
| Respiratory, Others | — | — | — | $421.0M | — | — |
| Seloken/Toprol-XL | — | — | — | $862.0M | $640.0M | — |
| Soliris | — | — | — | $3.76B | $3.15B | $1.84B |
| Strensiq | — | — | — | $958.0M | $1.15B | $1.68B |
| Total Oncology | — | — | — | $14.63B | $17.14B | $23.70B |
| Total Other medicines | — | — | — | $1.63B | $1.18B | $972.0M |
| Ultomiris. | — | — | — | $1.97B | $2.96B | — |
| Vaxzevria | — | — | — | $1.80B | $12.0M | — |
| Andexxa | — | — | — | $150.0M | $182.0M | — |
| Saphnelo | — | — | — | $116.0M | $280.0M | $686.0M |
| Ultomiris | — | — | — | — | — | $4.72B |
By Geography
| Segment | 2025 |
|---|---|
| Asia, Africa And Australasia | $13.37B |
| Europe excluding the United Kingdom | $13.46B |
| The Americas | $27.56B |
| UNITED KINGDOM | $4.36B |